Changes in Presentation, Treatment, and Survival of Patients with Hepatocellular Carcinoma in Damietta, Egypt, 2007–2019: A Retrospective Monocentric Cohort Study

References

• Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi:10.1155/2014/437971
   PubMedGoogle Scholar
• Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37:45–53. doi:10.1111/liv.13186
   PubMed Web of Science ®Google Scholar
• Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355:887–891. doi:10.1016/S0140-6736(99)06527-7
   PubMed Web of Science ®Google Scholar
• Arafa N, El Hoseiny M, Rekacewicz C, et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol. 2005;43:418–424. doi:10.1016/j.jhep.2005.03.021
   Web of Science ®Google Scholar
• Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. doi:10.4103/jcar.JCar_9_16
   PubMedGoogle Scholar
• Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367–1377. doi:10.1002/cncr.24817
   PubMed Web of Science ®Google Scholar
• Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016;122:2512–2523. doi:10.1002/cncr.30103
   PubMed Web of Science ®Google Scholar
• Kao W-Y, Su C-W, Chau G-Y, Lui W-Y, Wu C-W, Wu J-C. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg. 2011;35:858–867. doi:10.1007/s00268-010-0928-z
   PubMed Web of Science ®Google Scholar
• Morisco F, Guarino M, Valvano MR, et al. Metabolic disorders across hepatocellular carcinoma in Italy. Liver Int. 2018;38(11):2028–2039. doi:10.1111/liv.13877
   Web of Science ®Google Scholar
• Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54:411–418. doi:10.1136/gut.2004.048124
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835–853. doi:10.1053/j.gastro.2015.12.041
   PubMed Web of Science ®Google Scholar
• Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One. 2014;9:e90929. doi:10.1371/journal.pone.0090929
   PubMed Web of Science ®Google Scholar
• National Cancer Registry Program of Egypt (NCRPE). Reports and Statistics – Damietta; 2012. Available from: http://cancerregistry.gov.eg/. Accessed January 19, 2023.
   Google Scholar
• El-Akel W, El-Sayed MH, El Kassas M, et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J Viral Hepat. 2017;24:262–267. doi:10.1111/jvh.12668
   PubMed Web of Science ®Google Scholar
• Esmat G, Elbaz T, Elsharkawy A, Abdullah M, El Kassas M. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev Anti Infect Ther. 2020;18:637–642. doi:10.1080/14787210.2020.1758065
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18
   PubMed Web of Science ®Google Scholar
• Maas M, Beets-Tan R, Gaubert J-Y, et al. Follow-up after radiological intervention in oncology: ECIO-ESOI evidence and consensus-based recommendations for clinical practice. Insights Imaging. 2020;11:83. doi:10.1186/s13244-020-00884-5
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–693. doi:10.1016/j.jhep.2021.11.018
   PubMed Web of Science ®Google Scholar
• Uno H, Claggett B, Tian L, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380–2385. doi:10.1200/JCO.2014.55.2208
   PubMed Web of Science ®Google Scholar
• Stensrud MJ, Røysland K, Ryalen PC. On null hypotheses in survival analysis. Biometrics. 2019;75:1276–1287. doi:10.1111/biom.13102
   Web of Science ®Google Scholar
• Royston P, Parmar MKB. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152. doi:10.1186/1471-2288-13-152
   PubMed Web of Science ®Google Scholar
• Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642. doi:10.1016/S0140-6736(17
   PubMed Web of Science ®Google Scholar
• Waziry R, Gomaa A, Waked I, Dore GJ. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab J Gastroenterol. 2018;19:26–32. doi:10.1016/j.ajg.2018.02.004
   Web of Science ®Google Scholar
• Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;24:86. doi:10.4103/jrms.JRMS_1017_18
   PubMed Web of Science ®Google Scholar
• Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two Phase III studies. J Hepatol. 2017;67:999–1008. doi:10.1016/j.jhep.2017.06.026
   PubMed Web of Science ®Google Scholar
• El Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C antiviral therapy in patients with successfully treated hepatocellular carcinoma: dancing with wolves. JHC. 2019;6:183–191. doi:10.2147/JHC.S206668
   Google Scholar
• El Kassas M, Funk AL, Salaheldin M, et al. Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis. J Viral Hepat. 2018;25:623–630. doi:10.1111/jvh.12854
   PubMed Web of Science ®Google Scholar
• Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut. 2022;71:593–604. doi:10.1136/gutjnl-2020-323663
   Web of Science ®Google Scholar
• Ranganathan P, Pramesh CS. Censoring in survival analysis: potential for bias. Perspect Clin Res. 2012;3:40. doi:10.4103/2229-3485.92307
   PubMedGoogle Scholar
• Lambert PC, Royston P. Further Development of flexible parametric models for survival analysis. Stata J. 2009;9:265–290. doi:10.1177/1536867X0900900206
   Web of Science ®Google Scholar